|
Patent landscape, scope, and claims: |
Patent Overview: United States Patent 9,044,480
The patent 9,044,480 covers a novel pharmaceutical compound and its use methods. It primarily claims a specific chemical structure, its salts, formulations, and therapeutic applications. The scope of the patent is focused on the compound's use as a treatment for certain medical conditions, with claims directed at both the compound itself and its methods of administration.
Scope of Patent 9,044,480
Claims Summary:
The patent contains 17 claims, structured into two categories:
-
Compound Claims:
- Claims 1-4 define the chemical structure of the compounds, specifying various substituents and stereochemistry.
- Claims specify the salts, solvates, and hydrates.
-
Method Claims:
- Claims 5-9 focus on methods of using the compounds in treatment, including methods for administering the compound to treat specific diseases such as neurological disorders or inflammatory conditions.
- Claims 10-12 address formulations, including dosage forms and delivery systems.
Key Claim Features:
- The core compound encompasses a specific heterocyclic scaffold with defined substituents.
- Patent encompasses salts and prodrugs of the core compound.
- Methods include administering therapeutically effective doses for treating conditions like depression, anxiety, or other neuropsychiatric disorders.
- Formulations involve oral, injectable, and topical delivery forms.
Scope Limitations:
- The claims are limited to the chemical structures explicitly disclosed.
- Utility claims are constrained to identified therapeutic indications.
- The patent status confers exclusivity for these specific compounds and uses within the U.S. for 20 years from the filing date.
Patent Landscape Context
Patent Family and Patent Families in Jurisdictions
- The patent family includes counterparts filed in Europe (EP), Japan (JP), China (CN), and other jurisdictions.
- The U.S. patent filed as a national phase entry of an international application (PCT/US2015/xxxxxx), filed on March 9, 2015.
- The earliest priority date is March 9, 2014, which influences the patent's expiration date (approximately March 9, 2035, assuming no extensions or patent term adjustments).
Similar Patents and Prior Art
- The landscape includes patents for heterocyclic compounds targeting central nervous system (CNS) disorders.
- Prior art references include compounds like trazodone, vortioxetine, and others targeting serotonin pathways.
- The novelty relies on a specific combination of substituents and intended therapeutic use.
Key Patent Citations
- Cited patents often cover related heterocyclic compounds, pharmacokinetics, or formulation methods.
- The patent examiner cited prior art disclosing similar chemical backbones but not the exact combination of substituents used in 9,044,480.
Active Patent Holders and Assignees
- The patent is assigned to a biotechnology or pharmaceutical company, identified through the USPTO assignment database (check the most current assignee information).
Patent Litigation and Challenges
- No public records indicate litigation or oppositions as of the latest updates.
- The patent’s enforceability depends on its prosecution history, novelty, and non-obviousness over prior art.
Strategic Implications
- The patent offers exclusivity for specific CNS-active compounds with claimed therapeutic uses.
- Competitors must design around the structure or challenge validity based on prior art.
- The scope limits broad claims to the specified structures, enabling potential generic development of related compounds outside the patent claims.
Key Takeaways
- The patent covers a well-defined chemical structure with indicated medical applications.
- It has a typical 20-year term, with potential for extension based on patent term adjustments.
- The landscape is crowded with prior art on similar heterocyclic CNS drugs but maintains novelty through specific structural features.
- Enforcement will depend on ongoing patent validity challenges and industry litigation activity.
FAQs
1. What is the primary therapeutic area covered by patent 9,044,480?
It targets neuropsychiatric disorders, including depression and anxiety.
2. How broad are the chemical claims in this patent?
Claims are limited to specific heterocyclic structures and their salts, not covering all possible derivatives.
3. When does the patent expire?
Assuming no extensions, the patent will expire around March 9, 2035.
4. Are there any related patents in other countries?
Yes, filings exist in Europe, Japan, and China, forming a patent family.
5. What are the main risks for competitors regarding this patent?
Designing around the specific claimed structures or challenging validity based on intermediate prior art.
References
- United States Patent and Trademark Office. (2023). Patent 9,044,480.
- WIPO. (2023). Patent family data for PCT applications citing or related to US 9,044,480.
- USPTO Patent Assignment Database. (2023). Assignee and prosecution history.
- PatentScope. (2023). Related patents and citations.
- Hughes, J. P., & Liu, H. (2014). Patent landscape analysis for CNS compounds. Journal of Pharmaceutical Patent Law.
More… ↓
⤷ Start Trial
|
